Sihuan Pharmaceutical: Revenue in 2025 is expected to be between 3.4-3.6 billion, with the net loss narrowing.

Four Rings Biology announced that the estimated revenue for 2025 is 340-360 million yuan, compared to 204 million yuan in the same period last year; the net profit attributable to the shareholders of the listed company is expected to be a loss of 30-40 million yuan, compared to a loss of 110 million yuan in the same period last year, increasing by 63.63%-72.73%. The increase in revenue is due to a significant increase in sales of seedlings at its wholly-owned subsidiary Morning Glory Ecological Park; the increase in net profit is due to reduced impairment losses and non-operating expenses at Morning Glory Ecological Park, as well as effective cost controls at its controlling subsidiary, Beijing Four Rings Biopharmaceuticals. Since the net profit was negative in 2024 and the revenue was less than 300 million yuan, the company's stock has been subject to delisting risk warning since April 30, 2025. If the financial indicators in 2025 meet certain conditions, the stock may be suspended or delisted.